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Letter to the Editor
SIADH After Influenza Vaccination
Since vaccine is given for disease prevention rather than treatment, it is understandable that the safety requirements 
for vaccines are high to ensure that the benefits outweigh the risks [1]. Adverse events following immunization may 
occur due to errors in administration, storage and transport of the vaccine, as well as the inherent vaccine proper-
ties [2]. The currently-employed World Health Organization criteria may not be sufficient for determining whether 
or not an adverse event is truly vaccine-related [3]. Nevertheless, causality is most likely for events that are unusual 
and closely follows vaccination [1]. Here, we report an elderly woman who developed syndrome of inappropriate 
antidiuretic hormone (SIADH) shortly after influenza vaccination.
Mrs. M was an 81-year-old lady with history of hypertension and minor stroke. Her medications included 
aspirin, famotidine and lisinopril with no recent change in the dosages. She had not taken any herbs or over-the-
counter drug. She had received trivalent inactivated influenza vaccine (Vaxigrip; Sanofi Pasteur, Lyon, France) as 
part of the territory-wide vaccination program 2 days before she was hospitalized for headache, malaise, myalgia, 
nausea, and vomiting once of undigested food.
On admission, she was euvolemic with no tachycardia. Her blood pressure was 165/66 mmHg. There was no 
focal neurological sign. The laboratory data on admission is shown in the Table. SIADH was diagnosed and fluid 
restriction of 1 L/day was implemented. Spot morning cortisol was 990 nmol/L. Thyroid function test, chest X-ray 
and plain computed tomography of the brain were normal. Serum sodium (in mmol/L) rose to 121, 124 and 130 
on days 3, 5 and 7 of hospitalization, respectively. Her symptoms subsided by day 7 and she was discharged 
without sequelae. Her serum sodium level remained normal 3 weeks after discharge.
Vaxigrip is an inactivated influenza vaccine containing three strains of influenza viruses—A/Brisbane/59/2007 
(H1N1)-like strain, A/Brisbane/10/2007 (H3N2)-like strain and B/Brisbane/60/2008-like strain (B/
Brisbane/60/2008—or the year 2009 to 2010 [4]. Common side-effects after influenza vaccination include local 
reactions such as pain, erythema and edema that occur in up to 57% of patients, but which usually disappear 
spontaneously within 1–2 days [4–6]. Systemic reactions such as fever, malaise, myalgia and arthralgia occur in 
26.4–52.3% of individuals [5,6].
Our patient developed systemic upset after influenza vaccination. She had hypotonic hyponatremia on admis-
sion. Although she had vomited once before admission, she was clinically euvolemic. Her normal hematocrit, 
normal serum urea and markedly elevated urinary sodium level spoke against a hypovolemic state.
Headache occurs in up to 10% of patients after influenza vaccination [7], but serious neurological complications 
such as Guillain-Barré syndrome [8–10], acute demyelinating encephalomyelitis [8] and chronic inflammatory de-
myelinating polyneuropathy [11] are rare. Hyponatremia or SIADH in the absence of a neurological syndrome has, 
however, not been reported. Given the myriad of neurological symptoms that may occur after influenza vaccination, 
it would be rational to add influenza vaccine to the long list of medications that may cause SIADH [12].
Our case may be categorized as being possibly vaccine-related, although it has been emphasized that adverse 
events temporally associated with vaccination might not necessarily be caused by the vaccine [13]. Case reports 
like ours, in principle, do not fulfil the requirements for hypothesis testing [2]. Faithfully adopting the current 
World Health Organization criteria in determining if an adverse event is truly vaccine-related is, however, unlikely 
to be sufficient. Therefore, we consider vigilant post-marketing surveillance and an effective reporting system to 
be of importance in building up the risk and safety profile of individual vaccines. Effectively conveying the risks 
and benefits of vaccination to the general public should be part and parcel of a mature health care system.
Table. Laboratory data on admission
Hematocrit 34.7%
Plasma levels of
  Urea 2.8 mmol/L
  Creatinine 59 μmol/L
 Sodium 117 mmol/L
 Potassium 3.5 mmol/L
  Glucose 6.3 mmol/L
Serum osmolality 251 mOsm/kg of water
Urine osmolality 361 mOsm/kg of water
Urine sodium 118 mmol/L
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